Expanding Access to Ultra-Sensitive Biomarker Testing: Urine as a Non-Invasive Matrix for Simoa Assays

Urine as a Non-Invasive Matrix for Ultra-Sensitive Biomarker Detection with Simoa®

The Simoa® platform extends its unmatched sensitivity to urine, enabling detection of low-abundance neurological and infectious disease biomarkers in a non-invasive, easy-to-collect matrix.

This application note highlights:

• Detection of brain-specific proteins (NfL, t-tau, GFAP, UCH-L1) in stroke patient urine
• A TB assay in urine with 98% specificity in HIV+ individuals

Simoa supports both ready-to-use and custom assays, making urine-based testing ideal for pediatric, geriatric, and global health research.

→ Download the full application note to explore how Simoa makes biomarker science more accessible than ever.